Gulliford Martin C, Charlton Judith, Prevost Toby, Booth Helen, Fildes Alison, Ashworth Mark, Littlejohns Peter, Reddy Marcus, Khan Omar, Rudisill Caroline
Department of Primary Care and Public Health Sciences, King's College London, London, UK; National Institutes for Health Research Biomedical Research Centre at Guy's and St Thomas' National Health Service Foundation Trust, London, UK.
Department of Primary Care and Public Health Sciences, King's College London, London, UK.
Value Health. 2017 Jan;20(1):85-92. doi: 10.1016/j.jval.2016.08.734. Epub 2016 Oct 21.
To estimate costs and outcomes of increasing access to bariatric surgery in obese adults and in population subgroups of age, sex, deprivation, comorbidity, and obesity category.
A cohort study was conducted using primary care electronic health records, with linked hospital utilization data, for 3,045 participants who underwent bariatric surgery and 247,537 participants who did not undergo bariatric surgery. Epidemiological analyses informed a probabilistic Markov model to compare bariatric surgery, including equal proportions with adjustable gastric banding, gastric bypass, and sleeve gastrectomy, with standard nonsurgical management of obesity. Outcomes were quality-adjusted life-years (QALYs) and net monetary benefits at a threshold of £30,000 per QALY.
In a UK population of 250,000 adults, there may be 7,163 people with morbid obesity including 1,406 with diabetes. The immediate cost of 1,000 bariatric surgical procedures is £9.16 million, with incremental discounted lifetime health care costs of £15.26 million (95% confidence interval £15.18-£15.36 million). Patient-years with diabetes mellitus will decrease by 8,320 (range 8,123-8,502). Incremental QALYs will increase by 2,142 (range 2,032-2,256). The estimated cost per QALY gained is £7,129 (range £6,775-£7,506). Net monetary benefits will be £49.02 million (range £45.72-£52.41 million). Estimates are similar for subgroups of age, sex, and deprivation. Bariatric surgery remains cost-effective if the procedure is twice as costly, or if intervention effect declines over time.
Diverse obese individuals may benefit from bariatric surgery at acceptable cost. Bariatric surgery is not cost-saving, but increased health care costs are exceeded by health benefits to obese individuals.
评估增加肥胖成年人及按年龄、性别、贫困程度、合并症和肥胖类型划分的人群亚组接受减肥手术的成本和效果。
采用队列研究,利用初级保健电子健康记录以及相关的医院利用数据,研究对象为3045例接受减肥手术的参与者和247537例未接受减肥手术的参与者。流行病学分析为概率马尔可夫模型提供依据,以比较减肥手术(包括等比例的可调节胃束带术、胃旁路术和袖状胃切除术)与肥胖的标准非手术治疗。结果指标为质量调整生命年(QALY)和每QALY阈值为30000英镑时的净货币效益。
在英国25万成年人的人群中,可能有7163例病态肥胖者,其中1406例患有糖尿病。1000例减肥手术的直接成本为916万英镑,终生医疗保健成本的增量贴现后为1526万英镑(95%置信区间为1518 - 1536万英镑)。糖尿病患者年数将减少8320(范围为8123 - 8502)。增量QALY将增加2142(范围为2032 - 2256)。每获得一个QALY的估计成本为7129英镑(范围为6775 - 7506英镑)。净货币效益将为4902万英镑(范围为4572 - 5241万英镑)。年龄、性别和贫困程度亚组的估计结果相似。如果手术成本翻倍,或者干预效果随时间下降,减肥手术仍然具有成本效益。
不同的肥胖个体可能以可接受的成本从减肥手术中获益。减肥手术并非节省成本,但肥胖个体获得的健康益处超过了增加的医疗保健成本。